AADE recently announced the launch of DANA, its newest resource for AADE members. DANA (Diabetes Advanced Network Access) keeps a host of information about the latest diabetes-related technology up-to-date and available, allowing healthcare providers to absorb and relay tips for the which apps to download and news about newly-released devices.

The day you send your T1D kiddo to college is a stressful one. Here is my advice on the 6 must-knows for your T1D college sick day.

The study conclusions found that Lexicon combined with optimized insulin therapy was associated with sustained A1C reduction, weight loss, lowered insulin doses, fewer episodes of severe hypoglycemia and improved patient-reported outcomes.

In general, biosimilar medicines are priced lower than the original product from which they are based. Drug price history suggests that at least two generics are needed on the market to lower costs in a meaningful way. If we look at biosimilar insulins, there does appear to be hope for decreased prices, but not as much as some may believe.

From an insulin pump that's the size of a backpack to stem cells hitching rides on what's the size of a bandaid, diabetes research has come a long way. It is not without tireless efforts from the scientific community, keen investors, visionaries and donors, alike, who have moved the needle.

Xeris Pharmaceuticals announced this week that the company has filed an NDA (new drug application) to the FDA for its Glucagon Rescue Pen.

Beyond Type 1 recently sat down with Dana Lewis, who shared with us how the OpenAPS system has changed her life. Her diabetes journey is fascinating, and Dana gave us a behind-the-scenes look at the technology that can seem almost too good to be true.

Research to cure and treat Type 1 mostly fits into five areas: 1) beta cell health and regeneration, 2) immunotherapy, 3) replacement beta cells, 4) device/technology innovation and 5) medications for glucose management.

CeQur, a company that develops and sells simple insulin delivery devices primarily for those with Type 2, has recently bought the Calibra insulin delivery patch from Johnson & Johnson.

Simon Watts is the Deputy CFO of Waitemata Districit Health Board in New Zealand

The race to find a more effective and non-evasive, injection-free therapy for patients with Type 1 diabetes involves many players. The remaining question is not when, but who is going to win: the tortoise or the hare?

I told him that giving himself insulin would make him go “low.” He wanted to go low now, of course, in order to attain that precious Sprite that sat in the fridge awaiting him. I didn’t ever tell him that insulin was as dangerous as it is life saving. I never thought I had to.

It is all too easy to be consumed by anger — and my final project showed me that even though I wasn’t able to find that “beauty,” that Whatever-It-Was-I-Thought-I-Needed-To-Make-Art wasn’t necessary.

“For a long time, everybody thought that Type 1 would be cured by immunosuppression,” said The Faustman Lab’s Dr. Denise L. Faustman, M.D., Ph.D., but the past 30 years of discovery “have proven that immunostimulation is what’s needed.”

On July 27, 2018, Douglas Cairns and Thor Dahl teamed up with Dexcom to beat the world record of most states visited in the US in 24 hours.